# Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke

Study · id `cardio:ct-nct03815292` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03815292](<https://clinicaltrials.gov/study/NCT03815292>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03815292

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 276 participants.

## Technical summary

Registry record NCT03815292. Randomized; quadruple masking; primary purpose treatment. Start 2018-10-19 (actual); primary completion 2020-01-27 (actual). Results posted on 2021-02-23.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 276 participants (enrolled count; ClinicalTrials.gov record NCT03815292, source copy `cardio:ctgov-nct03815292-2021-02-23`, retrieved 2026-10-26)
- Started: 2018-10-19 (actual) (ClinicalTrials.gov record NCT03815292, source copy `cardio:ctgov-nct03815292-2021-02-23`, retrieved 2026-10-26)
- Primary completion: 2020-01-27 (actual) (ClinicalTrials.gov record NCT03815292, source copy `cardio:ctgov-nct03815292-2021-02-23`, retrieved 2026-10-26)
- Completion: 2020-01-27 (actual) (ClinicalTrials.gov record NCT03815292, source copy `cardio:ctgov-nct03815292-2021-02-23`, retrieved 2026-10-26)
- Results first posted: 2021-02-23 (ClinicalTrials.gov record NCT03815292, source copy `cardio:ctgov-nct03815292-2021-02-23`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT03815292, source copy `cardio:ctgov-nct03815292-2021-02-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03815292-2021-02-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
- Condition: Mild Cognitive Impairment
- Condition: Ischemic Stroke
- Intervention (Drug): MMH-MAP
- Intervention (Drug): Placebo
- Lead sponsor: Materia Medica Holding
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: a9f3bca3d8b4245793c213f39ef6d8a8f76f1176d2bfed2661e33e41acb83aa5
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
